GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 511,200 shares, a growth of 6.5% from the November 30th total of 479,800 shares. Based on an average daily volume of 1,640,000 shares, the days-to-cover ratio is presently 0.3 days.

GeoVax Labs Trading Up 1.2 %

GOVX stock traded up $0.03 during mid-day trading on Wednesday, hitting $2.47. 1,947,878 shares of the stock were exchanged, compared to its average volume of 2,317,359. The business has a fifty day moving average price of $2.39 and a 200 day moving average price of $2.81. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same quarter in the previous year, the firm earned ($4.80) EPS. Equities analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission (SEC). 6.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GOVX has been the subject of several research analyst reports. Alliance Global Partners assumed coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a report on Friday, November 15th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.